Filtered By:
Condition: Heart Failure
Education: Study
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 183 results found since Jan 2013.

Extent of mural thrombus is not associated with increased 5-year mortality following elective AAA repair
CONCLUSIONS: In our experience, the extent of mural thrombus in AAA does not influence long-term survival after elective repair. AAA repair may provide protection against circulating components of mural thrombus which have the potential to promote atherosclerotic-related adverse events. Patients with renal insufficiency and larger AAA have increased risk of mortality 5 years after elective repair.PMID:35331063 | DOI:10.1177/17085381211063282
Source: Vascular - March 25, 2022 Category: Surgery Authors: Bilal Siddiq Matthew Dejong Emily Decicco Tara Zielke Melissa D'Andrea Bernadette Aulivola Matthew Blecha Source Type: research

CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol
DISCUSSION: This trial will differ from others by: (1) detailed repeated hemodynamic assessment including arteriovenous access flow and (2) by careful assessment of adequate hydration to avoid confusion between HF and water overload.PMID:35676802 | DOI:10.1177/11297298221099843
Source: The Journal of Vascular Access - June 9, 2022 Category: Surgery Authors: Jan Malik Anna Valerianova Satu Sinikka Pesickova Zdenka Hruskova Vladimira Bednarova Pavel Michalek Vladimir Polakovic Vladimir Tesar Source Type: research

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
CONCLUSIONS: HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.PMID:36005278 | DOI:10.1002/14651858.CD013751.pub2
Source: Cochrane Database of Systematic Reviews - August 25, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Allison Jaure Elisabeth M Hodson Marinella Ruospo Tess E Cooper Deirdre Hahn Valeria M Saglimbene Jonathan C Craig Giovanni Fm Strippoli Source Type: research

Acute kidney injury and risk of cardiovascular outcomes: A nationwide cohort study
CONCLUSION: Non-selected patients aged 50 years or above with AKI during admission had significantly higher one-year risk of cardiovascular event or death, especially, but not only due to heart failure, independent of age and eGFR.PMID:36210122 | DOI:10.1016/j.nefroe.2022.06.003
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - October 9, 2022 Category: Urology & Nephrology Authors: Philip Andreas Schytz Paul Blanche Anders Bonde Nissen Christian Torp-Pedersen Gunnar H Gislason Karl Emil Nelveg-Kristensen Kristine Hommel Nicholas Carlson Source Type: research

Costs of major complications in people with and without diabetes in Tasmania, Australia
ConclusionsDiabetes complications are costly, and the costs are higher in people with diabetes than without diabetes. Our results can be used to populate diabetes simulation models and will support policy analyses to reduce the burden of diabetes.PMID:36375176 | DOI:10.1071/AH22180
Source: Australian Health Review - November 14, 2022 Category: Hospital Management Authors: Ngan T T Dinh Barbara de Graaff Julie A Campbell Matthew D Jose Burgess John Timothy Saunder Alex Kitsos Nadine Wiggins Andrew J Palmer Source Type: research

The Effects of Mineralocorticoid Receptor Antagonists on Cardiovascular Outcomes in Patients With End ‐Stage Renal Disease and Heart Failure
ConclusionsIn patients undergoing regular dialysis who are diagnosed with heart failure, the use of MRAs is associated with lower risks of all-cause mortality and CV death. The benefits of MRA treatment in heart failure may persist in patients with ESRD. Further investigations through randomized controlled trials are needed to assess the efficacy and safety of MRAs in this high-risk population.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - November 21, 2022 Category: Cardiology Authors: Donna Shu ‐Han Lin, Fang‐Ju Irene Lin, Yu‐Sheng Lin, Jen‐Kuang Lee, Yen‐Hung Lin Tags: Research Article Source Type: research

Pitavastatin Compared with Differential Intervention Trial by Standard Therapy on Cardiovascular Events in Patients with Dyslipidemia on Chronic Hemodialysis (DIALYSIS): A Randomized Controlled Trial
Conclusion: Our study has demonstrated that aggressive intervention with pitavastatin is more effective than the standard (dietary) therapy for improving the clinical outcomes in patients with dyslipidemia on chronic hemodialysis.Blood Purif
Source: Blood Purification - January 30, 2023 Category: Hematology Source Type: research

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionThere was no evidence of increased risk of cardiovascular events or mortality with roxadustat compared with ESA in patients with anemia who have NDD or ID-DD CKD. Although TEAEs occurred commonly in both the roxadustat and ESA groups, patients infrequently discontinued the study drug because of an adverse event.Clinical Trial Registration NumbersDOLOMITES, 1517-CL-0610 [NCT02021318]; HIMALAYAS, FGCL-4592-063 [NCT02052310]; SIERRAS, FGCL-4592-064 [NCT02273726]; and ROCKIES, D5740C00002 [NCT02174731].
Source: Advances in Therapy - February 7, 2023 Category: Drugs & Pharmacology Source Type: research

Risk of Major Cardiovascular Disease after Exposure to Contrast Media: A Nationwide Population-Based Cohort Study on Dialysis Patients
Metabolites. 2023 Feb 13;13(2):266. doi: 10.3390/metabo13020266.ABSTRACTContrast associated kidney injury is caused by side effects of iodinated contrast media (ICM), including inflammation. Chronic inflammation among dialysis patient contributes to atherosclerosis, which leads to simultaneous conditions of the kidney, brain, and vasculature. Data to investigate the pathologic effects of ICM on cardiovascular complications in dialysis patients are lacking. Dialysis patients who had been exposed to ICM from computed tomography (ICM-CT) were allocated as the ICM-CT cohort (N = 3751), whereas dialysis patients without ICM exp...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Shih-Ting Huang Tung-Min Yu Chia-Hsin Chen Yun-Chung Cheng Ya-Wen Chuang Cheng-Hsu Cheng Jia-Sin Liu Chih-Cheng Hsu Ming-Ju Wu Source Type: research